Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100
Lantheus Holdings Inc (LNTH) shares dropped 6.4% to $102.82 but are still considered overvalued according to GuruFocus's GF Value™ which estimates its intrinsic value at $90.77. Despite a strong GF Score™ of 82/100, indicating robust fundamentals in profitability and growth, its overvaluation and weak momentum score of 3/10 suggest caution for investors. The absence of insider transactions in the last three months further highlights the perceived risk of a current entry point.
Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ (LNTH) Risk Profile?
Lantheus Holdings received a Complete Response Letter from the FDA for its LNTH-2501 PET imaging kit due to third-party manufacturing facility issues, not product safety or efficacy. Concurrently, the company was added to the Russell 2000 Defensive and Growth-Defensive Indexes, increasing its visibility as a defensive healthcare equity. This article discusses how the FDA delay, combined with the index additions, impacts Lantheus's financial outlook and risk profile, noting that the company's growth hinges on resolving manufacturing issues and the success of its new PYLARIFY formulation.
LNTH - Lantheus Holdings Inc Latest SEC Filings
This article provides the latest SEC filings information for Lantheus Holdings Inc. (LNTH), along with comprehensive financial data, performance metrics, and key ratios. It includes details on the company's market capitalization, income, sales, P/E ratio, insider ownership, institutional ownership, and stock performance across various timeframes.
Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ (LNTH) Risk Profile?
Lantheus Holdings (LNTH) recently faced a delay for its LNTH-2501 PET imaging kit due to FDA-cited third-party manufacturing facility issues, not product efficacy concerns. Despite this setback, the company was added to the Russell 2000 Defensive and Growth-Defensive Indexes, potentially increasing its visibility among defensive healthcare investors. This article explores how these contrasting developments could reframe Lantheus's growth narrative and risk profile, emphasizing the importance of resolving manufacturing issues while also navigating product concentration risks.
Lantheus Holdings Inc focuses on diagnostic imaging and radiopharmaceutical growth
Lantheus Holdings Inc is a specialized medical technology company that develops diagnostic imaging agents and radiopharmaceuticals for cardiology and oncology. The company's products help physicians visualize disease processes and improve diagnostic accuracy. Lantheus aims for long-term growth by enhancing its portfolio, expanding manufacturing capabilities, and engaging in collaborations within the regulated healthcare market.
Lantheus Holdings stock hits 52-week high at 111.52 USD
Lantheus Holdings stock reached a new 52-week high of $111.52, reflecting a strong 39.74% increase over the past year and investor confidence. This comes despite a recent FDA regulatory setback for its LNTH-2501 imaging kit due to manufacturing issues. Analysts like Citizens and Mizuho maintain "Outperform" ratings for Lantheus, with price targets of $115, amid reports of a potential $7 billion takeover offer from privately held Curium.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio
Lantheus Holdings, Inc. (LNTH) is a strong player in the healthcare sector, particularly in diagnostic and therapeutic products, indicated by its $7.15 billion market cap and robust stock performance. The company exhibits impressive financial health with a 23.48% Return on Equity and substantial free cash flow, despite a modest revenue growth. Analysts maintain overwhelmingly positive ratings, supported by an innovative product portfolio and strategic collaborations, positioning LNTH for future growth in precision medicine.
Lantheus Holdings (LNTH) New Product Narrative Keeps Valuation Questions In Focus
Lantheus Holdings (LNTH) shares have recently seen significant movement, prompting investors to re-evaluate the company's valuation in light of its diagnostics and radiopharmaceutical portfolio. While market ratios suggest a balanced valuation, the company is considered modestly overvalued by the most widely followed fair value estimate of $104.08. Upcoming product launches are expected to diversify revenue, but the valuation hinges on successful management of competition and reduced reliance on its current flagship product, PYLARIFY.
FDA issues complete response letter for Lantheus’ NET imaging drug
The FDA has issued a Complete Response Letter for Lantheus Holdings Inc.'s NET imaging drug, LNTH-2501, due to unresolved manufacturing issues at a third-party facility. The FDA's decision is not related to the drug's safety or efficacy data. Despite this setback, Lantheus shares remain near their 52-week high, and the company is working with its manufacturing partner and the FDA to address the concerns.
Enterprise value to revenue forward of Lantheus Holdings, Inc. – NASDAQ:LNTH
This page displays the enterprise value to revenue forward for Lantheus Holdings, Inc. (NASDAQ: LNTH). It provides financial data and historical values for this specific metric. The content appears to be a financial data point from TradingView related to the company's valuation.
Price to sales forward of Lantheus Holdings, Inc. – NASDAQ:LNTH
This page displays the forward Price to Sales ratio for Lantheus Holdings, Inc. (NASDAQ:LNTH). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company.
Lantheus stock falls after FDA rejects drug application
Lantheus Holdings Inc. shares dropped after the FDA issued a Complete Response Letter for its LNTH-2501 drug application, citing unresolved manufacturing issues at a third-party facility. The FDA's decision was not related to the clinical safety or efficacy data of the drug, which is designed for neuroendocrine tumors. Lantheus is working with its manufacturing partner and the FDA to resolve the facility-related concerns.
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues
The U.S. FDA has declined to approve Lantheus Holdings' diagnostic imaging kit, LNTH-2501, for cancer tumors due to unresolved issues at a third-party manufacturing facility. This marks a setback for Lantheus, although the company stated that the FDA raised no concerns about the clinical performance, safety, or efficacy of the kit itself. Analysts view this as a minor setback, and the company's shares were marginally down in extended trading.
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
Lantheus announced that the FDA issued a Complete Response Letter for its New Drug Application for LNTH-2501, a diagnostic imaging agent for neuroendocrine tumors. The FDA's decision was due to unresolved manufacturing conditions at a third-party facility, not concerns about the drug's safety, efficacy, or data. Lantheus is working with its partner and the FDA to address these issues to bring LNTH-2501 to patients.
Price to book forward of Lantheus Holdings Inc – XETR:0L8
This article focuses on the "Price to book forward" metric for Lantheus Holdings Inc (XETR:0L8) as presented on TradingView. It appears to be a financial data snippet or a specific page from a financial tracking platform, indicating that the market for this stock is currently closed with no trades. The content describes the location of this financial data within the TradingView platform's market segment for Germany, specifically under "Stocks," "Health Technology," and "Medical Specialties."
Lantheus Holdings Inc Actuals & Estimates (NASDAQ:LNTH)
This article provides an overview of Lantheus Holdings, Inc. (NASDAQ:LNTH) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals and estimates for earnings and revenue, and key financial metrics like EBITDA. The company does not pay dividends and has 1.19K employees as of June 28, 2026.
LNTH Forecast — Price Target — Prediction for 2027
This article provides a detailed analyst forecast for Lantheus Holdings, Inc. (LNTH) stock for 2027, including a price target of 107.82 USD, with a max estimate of 117.00 USD and a min estimate of 94.00 USD. It covers various financial metrics such as price performance, market capitalization, earnings, revenue, and EBITDA. The analysis also includes current stock information, employee count, and technical analysis ratings.
Earnings Beat And Cautious Outlook Could Be A Game Changer For Lantheus Holdings (LNTH)
Lantheus Holdings (LNTH) recently surpassed Q1 analyst expectations for revenue and EPS due to strong demand for key products, while also reiterating its long-term plan. However, the company's full-year revenue guidance unexpectedly fell below analyst forecasts, indicating a cautious outlook despite the strong quarterly performance. This blend of strong quarterly results and conservative full-year projections suggests a nuanced investment narrative for Lantheus, focusing on near-term execution balanced against ongoing market pressures and competitive landscape.
Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest
This article analyzes the Q1 2026 earnings for healthcare equipment and supplies stocks, highlighting top performers like Lantheus (NASDAQ:LNTH) and STAAR Surgical (NASDAQ:STAA), and weaker performers such as Stryker (NYSE:SYK). It discusses industry trends, including innovation, an aging population, and challenges like pricing pressure and geopolitical risks.
Lantheus Holdings stock hits 52-week high at 107.99 USD By Investing.com
Lantheus Holdings Inc. (LNTH) stock reached a 52-week high of $107.99, demonstrating strong market performance with a significant year-to-date return of 59.58%. This achievement coincides with the company reporting strong Q1 2026 financial results, surpassing analyst expectations, and ongoing discussions regarding a potential $7 billion acquisition by Curium. Mizuho has reacted by raising its price target for Lantheus to $115, maintaining an Outperform rating.
Lantheus Holdings Inc (LNTH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of the shareholder structure of Lantheus Holdings Inc (LNTH), detailing its major shareholders and institutional holdings. It lists the top institutional investors, including BlackRock, Janus Henderson Investors, and Farallon Capital Management, and categorizes shareholders by type. The article also presents historical institutional shareholding data and details recent shareholder activity, along with related ETFs.
Lantheus (LNTH) Proxy filing Summary
Lantheus (LNTH) recently filed a proxy statement detailing its upcoming annual meeting on April 30, 2026. Key items for shareholder vote include the election of four Class II directors, advisory votes on executive compensation, and a proposal to declassify the Board of Directors. Shareholders will also vote on approving the 2026 Amended and Restated Equity Incentive Plan and ratifying Deloitte & Touche LLP as the independent auditor.
Lantheus Holdings Inc (LNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Lantheus Holdings Inc (LNTH), detailing its performance by business segments such as PYLARIFY, DEFINITY, TechneLite, Strategic partnerships, and Neuraceq. It presents revenue figures and proportions for each segment. The article also notes that relevant regional and profit contribution data have not yet been disclosed by the company.
Lantheus Holdings Inc (LNTH) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Lantheus Holdings Inc's (LNTH) dividend and stock split history. It notes that no dividends have been distributed by the company over the past five years, and there is no data available for past stock splits. The page also includes current stock price information and market capitalization for LNTH.
Lantheus Holdings Inc (LNTH) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Lantheus Holdings Inc (LNTH), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that most analysts recommend a "Buy" for the stock, with expected revenue of $363.12M for the next quarter. The company's EPS for the previous quarter was $0.83 against a market expectation of $1.83, with the next quarter's EPS projected at $1.30.
Lantheus Holdings Inc (LNTH) Institutional Confidence
Lantheus Holdings Inc (LNTH) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 10.60% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder.
Why (LNTH) Price Action Is Critical for Tactical Trading
This article analyzes Lantheus Holdings Inc. (LNTH) stock, highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels. It provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide tactical trading decisions.
Lantheus (LNTH) Stock And The Valuation Implications Of Its Award-Winning Imaging Agent
Lantheus (LNTH) recently received SNMMI's Image of the Year award for its investigational PET/CT agent LNTH-2513, leading to increased attention as its stock trades at US$104.67 with significant recent and long-term gains. Despite a narrative suggesting it's 1% overvalued, the company's expanding Alzheimer's disease imaging franchise and robust revenue figures indicate potential for future growth. The article advises investors to review underlying data to assess the balance between risks and rewards, particularly given the finely balanced sentiment on its valuation.
Lantheus (LNTH) Stock And The Valuation Implications Of Its Award-Winning Imaging Agent
Lantheus Holdings (LNTH) recently received an Image of the Year award for its investigational PET/CT agent, LNTH-2513, and is set to appear at a Goldman Sachs healthcare conference. The stock has shown strong performance over various timeframes, with a 5-year total shareholder return of 316.02%. While the current narrative suggests the stock is about 1% overvalued, its valuation is finely balanced due to the expansion of its Alzheimer's imaging franchise and projected growth in the U.S. PET imaging market.
Lantheus (LNTH) Stock And The Valuation Implications Of Its Award-Winning Imaging Agent
Lantheus (LNTH) recently gained attention following its investigational PET/CT agent receiving SNMMI’s Image of the Year award, coinciding with strong stock performance and an intrinsic value estimate suggesting a discount. While the current narrative places its fair value near its trading price, driven by the expansion of its Alzheimer's disease imaging franchise and anticipated revenue growth, the valuation hinges on product performance and acquisitions. The article explores whether the market fully prices in its future growth potential, considering its P/E ratio relative to peers.
How SNMMI’s ‘Image of the Year’ Win For LNTH-2513 At Lantheus (LNTH) Has Changed Its Investment Story
Lantheus's investigational PET imaging agent LNTH-2513 received SNMMI’s 2026 “Image of the Year” for its high diagnostic accuracy in detecting acute deep vein thrombosis and pulmonary embolism. This recognition expands Lantheus's radiopharmaceutical potential beyond oncology into thrombotic disease. While the award highlights pipeline depth, the near-term focus remains on PYLARIFY's new formulation and reimbursement, with LNTH-2513 offering longer-term diversification to reduce reliance on a single product.
How SNMMI’s ‘Image of the Year’ Win For LNTH-2513 At Lantheus (LNTH) Has Changed Its Investment Story
Lantheus (LNTH) recently won SNMMI's 2026 "Image of the Year" for its investigational PET imaging agent LNTH-2513, recognized for high diagnostic accuracy in detecting acute deep vein thrombosis and pulmonary embolism. This award highlights Lantheus's pipeline depth in thrombotic imaging and its efforts to diversify beyond oncology, although the near-term investment focus remains on the PYLARIFY formulation and reimbursement. While analysts project significant revenue and earnings growth, the company faces potential challenges from PSMA pricing pressure and reimbursement shifts.
Lantheus Holdings stock hits 52-week high at 104.05 USD By Investing.com
Lantheus Holdings (LNTH) stock reached a new 52-week high of $104.05, demonstrating a 59% surge over the last six months and a 29.72% increase over the past year. Despite a strong market performance and a "GREAT" Financial Health score according to InvestingPro, the stock currently appears overvalued relative to its Fair Value. The company recently reported strong Q1 2026 financial results, exceeding analyst expectations, and is in discussions for a potential $7 billion takeover by Curium, prompting Mizuho to raise its price target to $115 with an Outperform rating.
Lantheus Holdings (Nasdaq:LNTH) - Stock Analysis
Lantheus Holdings (LNTH) is trading below its fair value with strong past earnings growth and projected future growth. The company is actively developing and commercializing diagnostic and therapeutic products for heart, cancer, and other diseases, including recognized advancements for its LNTH-2513 PET/CT imaging agent in thrombosis detection and FDA approval for PYLARIFY TruVu for prostate cancer. Analyst price targets have seen various adjustments, reflecting both optimism regarding its pipeline and market opportunities, and caution regarding PYLARIFY challenges and growth forecasts.
Lantheus Holdings Inc at Goldman Sachs Healthcare Conference Transcript
This article provides a transcript of Lantheus Holdings Inc.'s presentation at the Goldman Sachs Healthcare Conference. John Wiggins, VP of External Manufacturing, discussed the company's strategic priorities for 2026 and 2027, highlighting its focus on diagnostic radiopharmaceutical agents. The summary also lists various past earnings calls and conference transcripts for Lantheus Holdings Inc.
LNTH: TruVu launches regionally in late 2024, expanding PYLARIFY access and driving market growth
Lantheus Holdings, Inc. (LNTH) is expanding access to PYLARIFY and Neuraceq, with TruVu launching regionally by the end of 2024 and nationwide in Q1 2025. This market growth is fueled by increased prostate cancer imaging and new neurology agents, alongside optimized manufacturing and reimbursement strategies. The information is based on an AI-generated summary of the Goldman Sachs 47th Annual Global Healthcare Conference 2026 Audio Transcript.
A Look At Lantheus Holdings (LNTH) Valuation After Award Recognition For LNTH-2513 Imaging Agent
Lantheus Holdings' investigational imaging agent LNTH-2513 received SNMMI’s Image of the Year award, putting the company back in focus. Despite recent strong share price performance and trading near analyst price targets, Simply Wall St assesses LNTH as 3% undervalued based on projected radiodiagnostic growth and margins. The company's pipeline includes multiple new product launches expected to diversify revenue and expand earnings.
0L8 Stock Price and Chart — XETR:0L8
This page provides a comprehensive overview of Lantheus Holdings Inc (0L8) stock performance on the XETR exchange, including its current price, key financials, and upcoming earnings dates. It also features analyst ratings, related stock ideas from TradingView users, and information on ETFs holding the stock. The article details Lantheus Holdings Inc's business, which involves diagnostic imaging and nuclear medicine products for healthcare professionals.
Cash from financing activities of Lantheus Holdings Inc – XETR:0L8
This article presents financial data for Lantheus Holdings Inc (XETR:0L8), specifically focusing on cash from financing activities. It displays a table with period values and percentage changes regarding this financial metric. The content highlights the company's financial performance within the Medical Specialties sector.
Lantheus (LNTH) Q4 2025 earnings summary
Lantheus (LNTH) reported full-year 2025 revenue of $1.546 billion, a 0.5% increase year-over-year, with Q4 revenue reaching $406.8 million, up 4%. The company strengthened its radiodiagnostic portfolio through acquisitions and divestitures, and advanced several late-stage pipeline assets. For 2026, Lantheus projects revenue between $1.4 billion and $1.45 billion, with adjusted diluted EPS between $5.00 and $5.25.
ETFs Investing in Lantheus Holdings Inc Stocks
This article lists various ETFs that hold stocks of Lantheus Holdings Inc, providing detailed financial data for each fund. The funds are sorted by market value and include information such as weight of Lantheus stock, issuer, management style, expense ratio, assets under management (AUM), price, percentage change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies, including passive and active management, and focus on different market capitalizations like mid-cap, small-cap, and total market.
LNTH News | LANTHEUS HOLDINGS INC (NASDAQ:LNTH)
This page provides a collection of recent news and analysis articles related to Lantheus Holdings Inc. (NASDAQ:LNTH). It includes updates on earnings reports, conference participations, product awards, and market analyses, indicating active discussion around the company's financial performance and strategic activities. The stock's current price and after-hours trading information are also displayed.
Why Is LNTH Stock Up After Hours?
Lantheus Holdings (LNTH) shares rose after hours following FDA approval of its PYLARIFY TruVu injection. This new formulation, designed for imaging prostate cancer lesions, offers similar diagnostic properties and effectiveness to the original Pylarify but is expected to improve manufacturing efficiency and supply flexibility. The company plans a Q4 2026 commercial launch, with customer transition designed to be minimally disruptive.
How Investors Are Reacting To Lantheus Holdings (LNTH) Award-Winning Thrombus-Specific PET/CT Diagnostic Breakthrough
Lantheus Holdings' investigational LNTH-2513 (18F-GP1) PET/CT diagnostic tool recently won SNMMI’s 2026 “Image of the Year” for its high diagnostic accuracy in detecting DVT and pulmonary embolism, along with its ability to visualize active thrombi. This recognition strengthens Lantheus's radiodiagnostic pipeline, aiming to diversify beyond its core PYLARIFY product and reduce concentration risk, even as pricing pressures and reimbursement shifts remain key investor concerns. The company's future growth also anticipates launches of a new PYLARIFY formulation and PNT2003, with revenue projected to reach $1.9 billion by 2029.
How Investors Are Reacting To Lantheus Holdings (LNTH) Award-Winning Thrombus-Specific PET/CT Diagnostic Breakthrough
Lantheus Holdings' investigational LNTH-2513 (18F-GP1) PET/CT diagnostic tool recently won the SNMMI’s 2026 “Image of the Year” award for its high diagnostic accuracy in detecting DVT. This breakthrough supports Lantheus's strategy to diversify its radiodiagnostic portfolio beyond PYLARIFY, potentially reducing concentration risk and bolstering future earnings growth. While near-term catalysts involve other product launches, LNTH-2513's success could shape the long-term investment narrative, provided the company navigates pricing pressures and reimbursement challenges effectively.
Lantheus (LNTH) director uses 381 shares for tax-withholding, retains over 27,000
Lantheus Holdings, Inc. director Gerard Ber reported a tax-related disposition of 381 shares of common stock on May 14, 2026, to cover a tax obligation, not from an open-market sale. The shares were valued at $96.67 each, and after this transaction, Ber directly holds 27,118 shares of Lantheus common stock. This event is categorized as a tax-withholding disposition, indicating administrative handling of taxes on equity compensation.
Lantheus (LNTH) CEO Heino reports 1,227-share tax withholding and updated holdings
Lantheus Holdings CEO Mary Anne Heino reported a routine equity activity involving the disposition of 1,227 shares of common stock at $96.67 per share for tax withholding purposes. Following this transaction, she directly holds 321,897 shares and indirectly owns additional shares through various family trusts. This filing provides transparency regarding insider stock activity and changes in beneficial ownership.
Lantheus Holdings Jumps 5.0% Amid Sector-Wide Rally
Lantheus Holdings Inc. (LNTH) surged 5.0% to $101.14, participating in a broad sector-wide rally that boosted specialty pharmaceutical stocks. The movement, which saw trading volume reach 720,211 shares, indicates a positive shift in investor sentiment for the drug manufacturing segment rather than company-specific news. Investors are advised to monitor whether this sector momentum is sustainable and if Lantheus can deliver operational results to justify the valuation.
Radiopharma firm Lantheus to speak at Goldman Sachs health event
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that John Wiggins, Vice President of External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th at 8:40 a.m. ET. A live webcast and 30-day replay will be available on the company’s investor website. This event is part of Lantheus's ongoing investor outreach efforts, with past conference participations typically showing neutral to negative short-term market reactions, while significant positive movements have historically been tied to strong earnings and regulatory approvals.
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Lantheus Holdings, Inc. announced that John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, at 8:40 a.m. ET. A live webcast and replay of the presentation will be available on the company's website. Lantheus is a leading radiopharmaceutical-focused company with 70 years of experience, aiming to improve patient outcomes.
